Swedish biotech Pila Pharma has announced an update to its preclinical obesity studies, concluding that the absence of an effect on body weight in rats was most likely caused by insufficient drug exposure rather than lack of efficacy. The company is now pressing ahead with clinical preparations.

Read the full article at biostock.se:
https://biostock.se/en/2026/04/pila-pharmas-prekliniska-resultat-forklaras-sannolikt-av-lag-lakemedelsexponering/
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

Follow BioStock
Stay up to date with the latest news, upcoming events, recent videos, and podcasts! Subscribe to our newsletters at https://www.biostock.se/newsletter
Follow BioStock on social media: LinkedIn and Facebook!  

About BioStock
BioStock is the leading digital hub for the Nordic life science sector. Focusing on biotechnology, medical technology, diagnostics, and drug development, we provide daily news updates, in-depth analyses, exclusive interviews, and innovation-promoting networking events – all to keep you informed about industry developments.  
BioStock – Connecting Innovation & Capital.